Clinical trial
Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of…
NCT00427544 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00427544 |
|---|---|
| Title | Study of the Safety, Tolerability, and PK of PRA-027 Administered to Women of Nonchildbearing Potential |
| Official title | Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRA-027 Administered Orally to Healthy Women of Nonchildbearing Potential |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Fibroid |
| Intervention type | Drug |
| Interventions | PRA-027 |
| Start date | Feb 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jan 29, 2007 |
| Last update posted | Dec 5, 2007 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: